Article Versions Notes

Kim JY, Park SY, Lee G, Cho G, Hwangbo S-A, Park J-H, Ko Y-J. Evaluation of an In-House Developed Foot-and-Mouth Disease Virus SAT 3 Vaccine Strain Based on Antigen Productivity and Inactivation Kinetics for Commercial Feasibility. Vaccines. 2026; 14(5):381. https://doi.org/10.3390/vaccines14050381

Kim, Jae Young, Sun Young Park, Gyeongmin Lee, Giyoun Cho, Seung-A Hwangbo, Jong-Hyeon Park, and Young-Joon Ko. 2026. "Evaluation of an In-House Developed Foot-and-Mouth Disease Virus SAT 3 Vaccine Strain Based on Antigen Productivity and Inactivation Kinetics for Commercial Feasibility" Vaccines 14, no. 5: 381. https://doi.org/10.3390/vaccines14050381

Kim, J. Y., Park, S. Y., Lee, G., Cho, G., Hwangbo, S.-A., Park, J.-H., & Ko, Y.-J. (2026). Evaluation of an In-House Developed Foot-and-Mouth Disease Virus SAT 3 Vaccine Strain Based on Antigen Productivity and Inactivation Kinetics for Commercial Feasibility. Vaccines, 14(5), 381. https://doi.org/10.3390/vaccines14050381